Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Sun Pharma gets rights to commercialize and manufacture lerodalcibep worldwide except the United States and China. LIB will receive an upfront payment, milestones and royalties; the drug is approved in the EU under the brand Lyrokaul.
Licensing deal with LIB Therapeutics covers Lerodalcibep, a once-monthly PCSK9 inhibitor, across markets excluding the US and ChinaSun Pharmaceutical Industries has signed a global licensing agreement with US-based LIB Therapeutics for Lerodalcibep, a once-monthly cholesterol-lowering drug, giving…